Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study

Cardiovascular Events throughout the Disease Course in Chronic Myeloid Leukaemia Patients Treated with Tyrosine Kinase Inhibitors—A Single-Centre Retrospective Study

Introduction. Cardiovascular risk factors, pre-existing comorbidities, molecular factors, and the direct effects of second- and third-generation BCR-ABL1 tyrosine kinase inhibitors on the vascular endothelium contribute to the progression of cardiovascular (CV) events, especially atherothrombotic co...

Full description

Bibliographic Details
Main Authors: Andreea Varga, Ioan Tilea, Dorina Nastasia Petra, Mariana-Cornelia Tilinca, Mirela Liana Gliga, Smaranda Demian
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Journal of Clinical Medicine
Subjects:
chronic myeloid leukaemia
tyrosine kinase inhibitors
cardiovascular risk
comorbidities
Online Access:https://www.mdpi.com/2077-0383/9/10/3269

Internet

https://www.mdpi.com/2077-0383/9/10/3269

Similar Items